INGR

Ingredion Inc. Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026, for Ingredion Incorporated, a global provider of ingredient solutions. The company operates through three reportable segments: Texture & Healthful Solutions (T&HS), Food & Industrial Ingredients–Latin America (F&II–LATAM), and Food & Industrial Ingredients–U.S./Canada (F&II–U.S./Canada). A defining event for the period is the announcement of a pending all-cash acquisition of Tate & Lyle PLC for approximately $3.5 billion, expected to close in the second half of 2027.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Decline: Net income attributable to Ingredion decreased 42% year-over-year for the quarter and 35% year-to-date. This was driven by a 29% drop in operating income.
• Margin Compression: Gross margin declined from 26% to 23% due to higher manufacturing costs and a thermal event at the Argo facility.
• Restructuring Charges: Restructuring and impairment charges surged to $45 million in Q2 2026 (vs. $3 million in Q2 2025), primarily due to the closure of the Cabo, Brazil facility ($43 million charge).
• Financing Costs: Financing costs increased to $55 million in Q2 2026 (vs. $12 million in Q2 2025), largely due to $47 million in foreign exchange hedging losses related to the pending Tate & Lyle acquisition.
• Divestiture Gain: The company recognized a $44 million net gain on the sale of its majority ownership in the Pakistan business, partially offsetting the decline in operating income.
• Segment Performance:
  • T&HS: Sales up 5% and operating income up 5% due to volume growth.
  • F&II–LATAM: Sales up 3% but operating income down 7% due to currency impacts and demand challenges.
  • F&II–U.S./Canada: Sales down 7% and operating income down 33% due to production challenges at the Argo facility.

Guidance, Outlook, and Risks

Outlook and Capital Allocation: Management expects to fund the $3.5 billion Tate & Lyle acquisition through existing cash, borrowings under new credit facilities (a $2.75 billion bridge facility and a $1.475 billion delayed draw term loan), and potential debt issuance. Capital investment commitments for the remainder of 2026 are anticipated to be between $450 million and $490 million.

Risks and Contingencies:

• Acquisition Risks: Completion of the Tate & Lyle deal is subject to regulatory approvals (including antitrust in the U.S., U.K., EU, and China) and shareholder approval. Failure to close could result in material losses on hedging instruments.
• Operational Risks: Ongoing production challenges at the Argo facility and the impact of the Cabo, Brazil closure continue to weigh on margins.
• Market Risks: Significant exposure to foreign currency fluctuations, particularly the British pound sterling related to the pending acquisition, and volatility in raw material costs (corn, tapioca).

Investor Verification Checklist

• Acquisition Financing: Verify the status of regulatory approvals for the Tate & Lyle acquisition and the terms of the new $4.2 billion credit facilities.
• Argo Facility Status: Confirm the timeline for resolving production challenges at the Argo facility and the impact on future U.S./Canada segment volumes.
• Restructuring Costs: Monitor the execution of the Cabo, Brazil closure and the realization of associated cost savings.
• FX Hedging Impact: Track the fair value changes of the derivative instruments hedging the Tate & Lyle consideration, which are recorded in earnings and caused significant volatility in Q2.
• Divestiture Proceeds: Confirm the deployment of the $127 million net cash proceeds from the Pakistan business sale.